Development and Evaluation of Anti-Dandruff Hair Gel: IJRPC 2011, 1
Development and Evaluation of Anti-Dandruff Hair Gel: IJRPC 2011, 1
ISSN: 22312781
ABSTRACT
In the present study, an attempt was made to develop Clotrimazole Anti-Dandruff hair gel.
The different formulation were developed using polymers such as Corbopol 940, Corbopol
934, PEG 200 etc. These polymers were selected based on their use in gel formulation. All
the formulations were evaluated Active Content, Physical appearance, PH, Viscosity,
Extrudability, Antifungal activity, Drug release Profile, Compatibility and Stability study.
In Stability study, formulation F7 was shows no appreciable changes as compared to other
formulation during the study period of three months. Formulation F7 was shows
maximum zone of inhibition to an Anti-fungal activity during in vitro study. Therefore F7
could be used as an effective formulation for Anti-Dandruff hair gel of clotrimazole as
compared to other formulation.
Keywords: Anti-Dandruff hair gel, Clotrimazole, Stability study and in vitro study.
936
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
937
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
the time for 2 hrs. The media was stirred using indicating the hair compatibility and shown in
magnetic bead hot plate magnetic stirrer. table no 3.
938
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
changes were found for the tested parameters. dandruff or seborrheic dermatitis. Anti-
The results were shown in Table – 10. dandruff hair gel containing 1.5% (F7) of
Clotrimazole with Corbopol 940 base could be
CONCLUSION used as an effective in treatment of Dandruff
The formulation of Anti-dandruff hair gel on scalp.
provides a method for treating a scalp
939
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
Table 8: Comparative In-Vitro Drug Release profiles of Hair Gels (F5 to F8)
% of drug release
S. No. Time
F5 F6 F7 F8
1 20 5.26 6.71 10.21 8.51
2 40 10.57 12.32 25.32 22.15
3 60 23.84 24.40 35.37 34.82
4 80 39.86 36.83 40.72 39.52
5 100 42.89 48.52 45.58 41.45
6 120 45.95 54.58 56.78 46.58
* Each reading is an average of three determinations
940
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
50
45
40
% of Drug Release
35
30
25
20
15
10
5
0
0 20 40 60 80 100 120 140
Tim e (in M in .)
1.95
log % of drug remaining
1.9
1.85
1.8
1.75
1.7
0 20 40 60 80 100 120 140
Tim e (in M in.)
1 .95
Log % Drug Remaining
1.9
1 .85
1.8
1 .75
1.7
1 .65
1.6
0 20 40 60 80 100 12 0 14 0
Time (in Min.)
941
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
60
% of Drug Released
50
40
30
20
10
0
0 20 40 60 80 100 120 140
Time (in Min.)
60
50
% of Drug Released
40
30
20
10
0
0 20 40 60 80 100 120 140
Time (in Min.)
2
Log % of Drug Remaining
1.95
1.9
1.85
1.8
1.75
1.7
1.65
1.6
0 20 40 60 80 100 120 140
Time (in Min.)
942
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
50
45
% of Drug Released
40
35
30
25
20
15
10
5
0
0 20 40 60 80 100 120 140
Tim e (in M in . )
2
Log % of Drug Remaining
1.95
1.9
1.85
1.8
1.75
1.7
1.65
0 20 40 60 80 100 120 140
Tim e (in M in.)
60
50
% of Drug Released
40
F5
F6
30
F7
F8
20
10
0
0 20 40 60 80 100 120 140
Tim e (in Min.)
943
IJRPC 2011, 1(4) Praveen et al. ISSN: 22312781
944